Patient Guide: A Study of Debio 0123 in Combination With Temozolomide in Adult Participants With Recurrent or Progressive Glioblastoma and of Debio 0123 in Combination With Temozolomide and Radiotherapy in Adult Participants With Newly Diagnosed Glioblastoma

Why Use Quri.ai for This Trial?

  • ✓ Simplified eligibility checker - know if you qualify in minutes
  • ✓ Direct contact with study coordinators at 17 locations
  • ✓ Plain language explanations of medical terms and procedures
  • ✓ Personalized enrollment support throughout your journey
  • ✓ Free service - no hidden fees or obligations
Trial ID: NCTNCT05765812
Status: 🟢 Enrolling Now
Condition: Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype, Astrocytoma, Grade III
Phase: PHASE1, PHASE2

Where You Can Participate

This study is available at 17 locations across the country.

Top locations include:
  • • Chicago, Illinois
  • • New York, New York
  • • New York, New York
  • • And 14 more locations

Loading interactive enrollment tools...

The full interactive experience will load momentarily

A Study of Debio 0123 in Combination With Temozolomide in Adult Participants With Recurrent or Progressive Glioblastoma and of Debio 0123 in Combination With Temozolomide and Radiotherapy in Adult Participants With Newly Diagnosed Glioblastoma - Join Clinical Trial NCTNCT05765812

How to Join This Clinical Trial - NCTNCT05765812

Learn how to participate in this PHASE1, PHASE2 trial studying an investigational therapy for Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype, Astrocytoma, Grade III. This study is currently enrolling participants.

Am I Eligible for This Clinical Trial?

This clinical research study is looking for participants with Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype, Astrocytoma, Grade III. Eligibility requirements include specific age ranges, health status, and medical history. Contact the study team to learn if you qualify.

Condition Being Studied
Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype, Astrocytoma, Grade III
Treatment Being Tested
Investigational treatment
Study Phase
PHASE1, PHASE2 - Safety and effectiveness study
Enrollment Status
Currently enrolling participants
Study Identifier
NCTNCT05765812 - ClinicalTrials.gov Identifier
Sponsored By
Study sponsor

What to Expect as a Participant

Participating in this clinical trial involves:

  • Initial screening to determine eligibility
  • Regular study visits and health assessments
  • Receiving the study treatment or placebo
  • Medical monitoring and follow-up care
  • Contributing to medical research that may help others
  • Potential access to new treatments before they're widely available

Clinical Trial Benefits and Compensation

Participants in this clinical research study may receive:

  • Close medical monitoring by healthcare professionals
  • Access to potential new treatments
  • Compensation for time and travel (varies by study)
  • No-cost study-related medical care
  • The opportunity to help advance medical knowledge

Where Is This Clinical Trial Located?

This study is enrolling participants at 17 locations. Find a study site near you:

Clinical Research Site

Chicago, Illinois 60611 - United States

Status: RECRUITING

Clinical Research Site

New York, New York 10016 - United States

Status: RECRUITING

Clinical Research Site

New York, New York 10021 - United States

Status: RECRUITING

Clinical Research Site

Dallas, Texas 75246 - United States

Status: NOT_YET_RECRUITING

Clinical Research Site

Houston, Texas 77030 - United States

Status: RECRUITING

Clinical Research Site

San Antonio, Texas 78229 - United States

Status: RECRUITING

Clinical Research Site

Salt Lake City, Utah 84112 - United States

Status: NOT_YET_RECRUITING

Clinical Research Site

Seattle, Washington 98109 - United States

Status: RECRUITING

Clinical Research Site

Barcelona, 08035 - Spain

Status: RECRUITING

Clinical Research Site

Donostia, 20014 - Spain

Status: NOT_YET_RECRUITING

And 7 more locations available. Contact us to find the nearest participating site.

How to Enroll in This Study

To learn more about participating in this PHASE1, PHASE2 clinical trial for Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype, Astrocytoma, Grade III:

  1. Review the eligibility criteria with your healthcare provider
  2. Contact the study team for a pre-screening interview
  3. Schedule an in-person screening visit if eligible
  4. Review and sign the informed consent form
  5. Begin participation in the clinical trial

Why Choose Quri.ai Study Finder

Quri.ai's Study Finder is the leading clinical trial business intelligence platform, helping BD professionals:

  • Discover clinical trials before competitors
  • Access exclusive contact information
  • Track sponsor pipelines and opportunities
  • Connect with decision makers directly
  • Win more business partnerships